Pharmacological approaches and strategies for therapeutic modulation of fibrinogen

Thrombosis Research

Volumn 87, Issue 1, 1997, Pages 1-36

  Handley, Dean A ^a   Hughes, Thomas E ^b  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Fibrates; Fibrin; Fibrinogen; IL 6; Inflammation; Thrombosis

Indexed keywords

AMLODIPINE; ANABOLIC AGENT; ANCROD; ANTIINFLAMMATORY AGENT; ASPARAGINASE; ATENOLOL; BATROXOBIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEZAFIBRATE; BIGUANIDE DERIVATIVE; BROMELAIN; CLOFIBRATE; DEFIBROTIDE; ECARIN; ETHYLESTRENOL; ETOFIBRATE; FENOFIBRATE; FIBRINOGEN; GEMFIBROZIL; HEPARIN; INTERLEUKIN 6; LISINOPRIL; NABUMETONE; NISOLDIPINE; PHENFORMIN; PRASTERONE; PREDNISOLONE; PROPRANOLOL; STANOZOLOL; UNINDEXED DRUG;

ATHEROSCLEROSIS; CLINICAL TRIAL; DIABETES MELLITUS; FIBRINOGEN SYNTHESIS; FIBRINOLYSIS; HUMAN; INFLAMMATION; INTRAVENOUS DRUG ADMINISTRATION; ISCHEMIC HEART DISEASE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SMOKING; STRESS; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOSIS;

EID: 0030861111     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(97)00091-1     Document Type: Article

References (242)

1. ERNST, E. Lowering the plasma fibrinogen concentration with drugs. Clin Pharmacol 11, 968-971, 1992.
2. MANNUCCI, P.M. and MARI, D. Fibrinogen as a model protein in epidemiology studies. Fibrinolysis 3, 51-52, 1993.
3. KROBOT, K., HENSE, H.W., CREMER, P., EBERLE, E. and KEIL, U. Determinants of plasma fibrinogen: Relation to body weight, waist-to-hip ratio, smoking, alcohol, age, and sex. Arterioscler Thromb 12, 780-788, 1992.
4. MARKOWE, H.L.J., MARMOT, M.G., SHIPLEY, M.J., BULPITT, C.J., MEADE, T.W., STIRLING, Y., VICKERS, M.V. and SEMMENCE, A. Fibrinogen: A possible link between social class and coronary heart disease. Br Med J 297, 1312-1314, 1985.
5. GANDA, O.P. and ARKIN, C.F. Hyperfibrinogenemia: An important risk factor for vascular complications in diabetes. Diabetes Care 75, 1245-1250, 1992.
6. COLLER, B.S., FRANK, R.N., MILTON, R.C. and GRALNICK, H.R. Plasma cofactors of platelet function: Correlation with diabetic retinopathy and hemoglobin Ala-c. Ann Intern Med 88, 311-316, 1978.
7. LOWE, G.D.O. Blood viscosity, lipoproteins, and cardiovascular risk. Circulation 85, 2329-2331, 1992.
8. ATENCIO, A.C., JOINER, K. and REEVE, E.B. Experimental and control systems studies of plasma fibrinogen regulation in rabbits. Am J Physiol 216, 764-772, 1969.
9. DORMANDY, J.A. and RIED, H.L. Controlled defibrination in the treatment of peripheral vascular disease. Angiology 29, 80-88, 1978.
10. DI MINNIO, G. and MANCINI, M. Drugs affecting plasma fibrinogen levels. Cardiovasc Drug Ther 6, 25-27, 1992.
11. VIRCHOW, P. Gesammelte Abhandlungen sur wissenschaftlichen Medizin. Frankfurt: Meidinger; 1856.
12. BLOMBÄCK, B. Fibrinogen and fibrin formation. In: Fibrinolytics and Antifibrinolytics. F. Markwardt (ed.), pp. 49-79, John Wiley, New York, NY (1979).
13. FULLER, G.M. Fibrinogen: A multifunctional acute phase protein. In: Acute Phase Proteins: Molecular Biology, Biochemistry, and Clinical Applications. A. Mackiewicz, I. Kushner and H. Baumann (eds.), pp. 169-183, Doubleday Inc., New York, NY (1993).
14. MCFARLANE, A.S., TODD, D. and CROMWELL, S. Fibrinogen catabolism in humans. Clin Sci 26, 415-420, 1964.
15. REGOECZI, E. Fibrinogen catabolism: Kinetics of catabolism following sudden elevation of the pool with exogenous fibrinogen. Clin Sci 38, 111-121, 1970.
16. REEVE, E.B., TAKEDA, Y. and ATENCIO, A.C. Some observations on the mammalian fibrinogen system in nonsteady and steady states. Protein Biol Fluids 14, 283-294, 1966.
17. HANTGAN, R.R., FRANCIS, C.W., SCHERAGA, H.A. and MARDER, V.J. Fibrinogen structure and physiology. Hemost Thromb 269, 281-282, 1987.
18. 2 macroglobulin, haptoglobin and fibrinogen in rats. Br J Exp Pathol 60, 434-440, 1979.
19. BOVILL, E.G., MCDONAGH, J., TRIPLETT, D.A., ARKIN, C.F., BRANDT, J.T., HAYES, T.E., KACZMAREK, E., LONG, T. and ROCK, W.A. Performance characteristics of fibrinogen assays: Results of the college of american pathologists proficiency testing program 1988-1991. Arch Pathol Lab Med 117, 58-66, 1993.
20. JELIC-IVANOVIC, Z. and PEVCEVIC, N. Fibrinogen determination by five methods in patients receiving streptokinase therapy. Clin Chem 36, 698-699, 1990.
21. GLEESON, M. and KINLAY, S. Choice of anticoagulant affects measurement of plasma fibrinogen. Clin Chem 39, 1754-1755, 1993.
22. ELLIS, B.C. and STRANSKY, A. A quick and accurate method for the determination of fibrinogen in plasma. J Lab Clin Med 9, 477-487, 1961.
23. MACART, M., KOFFI, A., HENOCQUE G., MATHIEU, J-F. and GUILBAUD, J-C. Optimized microturbidimetric assay for fibrinogen. Clin Chem 35, 211-214, 1989.
24. JANOTOVA, R. and STERN, P. Generalization of microturbidimetric assay of fibrinogen. Clin Chem 38, 440-441, 1992.
25. BLAISDELL, F.S. and DODDS, W.J. Evaluation of two microhematocrit methods for quantitating plasma fibrinogen. J Am Vet Med Assoc 171, 340-342, 1977.
26. MILLAR, H.R., SIMPSON, J.G. and STALKER, A.L. An evaluation of the heat precipitation method for plasma fibrinogen estimation. J Clin Pathol 24, 827-830, 1971.
27. RAMPLING, M.W. and GAFFNEY, P.J. The sulfite precipitation method for fibrinogen measurement; Its use on small samples in the presence of fibrinogen degradation products. Clin Chim Acta 67, 43-52, 1976.
28. ALKHAIRY, K.S. and BAMGBOYE, E.A. Estimation of plasma fibrinogen from the difference in plasma and serum viscosities: A pilot study. Med Sci Res 20, 933-935, 1992.
29. WIMAN, B. and RANBY, M. Determination of soluble fibrin in plasma by a rapid and quantitative spectrophotometric assay. Thromb Haemost 55, 189-193, 1986.
30. CROSS, S. and MORRILL, R. Fibrinogen: A comparison of quantitative methods. Clin Hemost Rev 23, 56-58, 1990.
31. GAFFNEY, P.J. and WONG, M.Y. Collaborative study of a proposed international standard for plasma fibrinogen measurement. Thromb Haemost 68, 428-432, 1992.
32. MACHIN S.J. and MACKIE, I.J. Routine measurement of fibrinogen concentration. Br Med J 307, 882-883, 1993.
33. EHRLY, A.M. Improvement of the flow properties of blood: A new therapeutical approach in occlusive arterial disease. Angiology 27, 188-196, 1976.
34. DORMANDY, J.A., HOARE, E., COLLEY, J., ARROWSMITH, D.E. and DORMANDY, T.L. Clinical, haemodynamic, rheological, and biochemical findings in 126 patients with intermittent claudication. Br Med J 4, 576-581, 1973.
35. MOLLER, L. and KRISTENSEN T.S. Plasma fibrinogen and ischaemic heart disease risk factors. Arterioscler Thrombosis 11, 344-350, 1991.
36. ELWOOD, P.C., YARNELL, J.W.G., PICKERING, J., FEHILY, A.M. and O'BRIEN, J.R. Exercise, fibrinogen, and other risk factors for ischaemic heart disease. Caerphilly prospective heart disease study. Br Heart J 69, 183-187, 1993.
37. HAM T.H. and CURTIS, F.C. Plasma fibrinogen response in man. Medicine 17, 413-445, 1938.
38. HANDA, K., KONO, S., SAKU, K., SASAKI, J., KAWANO, T., SASAKI, Y., HIROKI, T. and ARAKAWA, K. Plasma fibrinogen levels as an independent indicator of severity of coronary atherosclerosis. Atherosclerosis 77, 209-213, 1989.
39. HEINRICH, J., BALLEISEN, L., SCHULTE, H., ASSMANN, G. and VAN DE LOO, J. Fibrinogen and factor VII in the prediction of coronary risk: Results from the procam study in the healthy men. Arterioscler Thromb 14, 54-59, 1994.
40. STONE, M.C. and THORP, J.M. Plasma fibrinogen - A major coronary risk factor. J R Coll Gen Pract 35, 565-569, 1985.
41. BANERJEE, A.K., PEARSON, J., GILLILAND, E.L., GOSS, D., LEWIS, J.D., STIRLING, Y. and MEADE, T.W. A six year prospective study of fibrinogen and other risk factors associated with mortality in stable claudicants. Thromb Haemostas 68, 261-263, 1992.
42. LEE, A.J., LOWE, G.D.O., WOODWARD, M. and TUNSTALL-PEDOE, H. Fibrinogen in relation to personal history of prevalent hypertension, diabetes, stroke, intermittent claudication, coronary heart disease, and family history. The scottish heart health study. Br Heart J 69, 338-342, 1993.
43. MEADE, T.W., BROZOVIC, M., CHAKRABARTI, R.R., HAINES, A.P., IMESON, J.D., MELLOWS, S., MILLER, G.J., NORTH, W.R.S., STIRLING, Y. and THOMPSON, S.G. Haemostatic function and ischaemic heart disease: principal results of the Northwick park heart study. Lancet ii, 533-537, 1986.
44. COULL, B.M., BEAMER, N., DE GARMO, P., SEXTON, G., NORDT, F., KNOX, R. and SEAMAN, G.V.F. Chronic blood hyperviscosity in subjects with acute stroke, transient ischemic attack, and risk factors for stroke. Stroke 22, 162-168, 1991.
45. TRACY, R.P., BOVILL, E.G., YANEZ, D., PSATY, B.M., FRIED, L.P., HEISS, G., LEE, M., POLAK, J.F. and SAVAGE, P.J. Fibrinogen and factor VIII, but not factor VII, are associated with measures of subclinical cardiovascular disease in the elderly. Arterioscler Thromb Vasc Biol 15, 1269-1279, 1995.
46. MONTALESCOT, G., ANKRI, A., VICAUT, E., DROBINSKI, G., GROSGOGEAT, Y. and THOMAS, D. Fibrinogen after coronary angioplasty as a risk factor for restenosis. Circulation 92, 31-38, 1995.
47. LEVENSON, J., GIRAL, P., RAZAVIAN, M., GARIEPY, J. and SIMON, A. Fibrinogen and silent atherosclerosis in subjects with cardiovascular risk factors. Arterioscler Thromb Vasc Biol 15, 1269-1279, 1995.
48. CORTELLARO, M., BOSCHETTI, C., COFRANCESCO, E., ZANUSSI, C., CATALANO, M., DE GAETANO, G., GABRIELLI, L., LOMBARDI, B., SPECCHIA, G., TAVAZZI, L., TREMOLI, E., DELLA VOLPE, A., POLLI, E. and the PLAT STUDY GROUP. The PLAT study: Hemostatic function in relation to atherothrombotic ischemic events in vascular disease patients. Arterioscler Thromb 12, 1063-1070, 1992.
49. LOWE, G.D.O., FOWKES, F.G.R., DAWES, J., DONNAN, P.T., LENNIE, S.E. and HOUSLEY, E. Blood viscosity, fibrinogen, and activation of coagulation and leukocytes in peripheral arterial disease and the normal population in the Edinburg artery study. Circulation 87, 1915-1920, 1993.
50. CERIELLO, A., TABOGA, C., GIACOMELLO, R., FALLETI, E., DE STASIO, G., MOTZ, E., LIZZIO, S., GONANO, F. and BARTOLI, E. Fibrinogen plasma levels as a marker of thrombin activation in diabetes. Diabetes 43, 430-432, 1994.
51. DUBREY, S.W., REAVELEY, D.R., SEED, M., LANE, D.A., IRELAND, H., O'DONNELL, M., O'CONNOR, B., NOBLE, M.I. and LESLIE, R.D.G., Risk factors for cardiovascular disease in IDDM: A study of identical twins. Diabetes 43, 831-835, 1994.
52. MEMEH, C.U. Differences between plasma viscosity and proteins of types 1 and 2 diabetic africans in early phase of diabetes. Horm Metab Res 25, 21-23, 1993.
53. MISSOV, R.M., STOLK, R.P., VAN DER BOM, J.G., HOFMAN, A., BOTS, M.L., POLS, H. A.P. and GROBBEE, D.E. Plasma fibrinogen in NIDDM: The Rotterdam study. Diabetes Care 19, 157-159, 1996.
54. SNOWDEN, C., HOULSTON, R., LAKER, M.F., KESTEVENS, P., ALBERTI, K.G. and HUMPHRIES, S.E. Plasma fibrinogen levels and fibrinogen genotype in noninsulin dependent diabetics. Dis. Markers 10, 159-168, 1992.
55. ERNST, E. Fibrinogen: The plot thickens. J Clin Epidemiol 45, 561-562, 1992.
56. DE FEO, P., VOLPI, E., LUCIDI, P., CRUCIANI, G., REBOLDI, G., SIEPI, D., MANNARINO, E., SANTEUSANIO, T., BRUNETTI, P. and BOLLI, G.B. Physiological increments in plasma insulin concentrations have selective and different effects on synthesis of hepatic proteins in normal humans. Diabetes 42, 995-1001, 1993.
57. DE FEO, P., GAN GAISANO, M. and HAYMOND, M.W. Differential effects of insulin deficiency on albumin and fibrinogen synthesis in humans. J Clin Invest 88, 833-840, 1991.
58. FUKATSU, A., MATSUO, S., TAMAI, H., SAKAMOTO, N., MATSUDA, T. and HIRANO, T. Distribution of interleukin-6 in normal and diseased human kidney. Lab Invest 65, 61-66, 1991.
59. SUZUKI, D., MIYAZAKI, M., NAKA, R., KOJI, T., YAGAME, M., JINDE, K., ENDOH, M., NOMOTO, Y. and SAKAI, H. In situ hybridization of interleukin 6 in diabetic nephropathy. Diabetes 44, 1233-1238, 1995.
60. MOROHOSHI, M., FUJISAWA, K., UCHIMURA, I. and NUMANO, F. The effect of glucose and advanced glycosylation end products on IL-6 production by human monocytes. Ann NY Acad Sci 748, 562-570, 1995.
61. BANKS, R.E., FORBES, M.A., STORR, M., HIGGINSON, J., THOMPSON, D., RAYNES, J., ILLINGWORTH, M.M., PERREN, T.J., SELBY, P.J. and WHICHER, J.T. The acute phase protein response in patients receiving SC IL-6. Clin Exp Immunol 102, 217-223, 1995.
62. BAUMANN, H. Hepatic acute phase reaction in vivo and in vitro. In vitro Cell Dev Biol 25, 115-126, 1989.
63. HEINRICH, P.C., CASTELL, J.V. and ANDUS, T. Interleukin-6 and the acute phase response. Biochem J 265, 621-636, 1990.
64. BILLIAR, T.R., CURRAN, R.D., WILLIAMS, D.L. and KISPERT, P.H. Liver nonparenchymal cells are stimulated to provide interleukin 6 for induction of the hepatic acute-phase response in endotoxemia but not in remote localized inflammation. Arch Surg 127, 31-37, 1992.
65. GEIGER, T. ANDUS, T., KLAPPROTH, J., HIRANO, T., KISHIMOTO, T. and HEINRICH, P.C. Induction of rat acute-phase proteins by interleukin 6 in vivo. Eur J Immunol 18, 717-721, 1988.
66. MARINKOVIC, S., JAHREIS, G.P., WONG, G.G. and BAUMANN, H. IL-6 modulates the synthesis of a specific set of acute phase plasma proteins in vivo. J Immunol 142, 808-812, 1989.
67. NETA, R., VOGEL, S.N., SIPE, J.D., WONG, G.G. and NORDAN, R.P. Comparison of in vivo effects of human recombinant IL 1 and human recombinant IL 6 in mice. Lymphokine Res 7, 403-411, 1988.
68. CAYOL, M., TAUVERON, I., RAMBOURDIN, F., PRUGNAUD, J., GACHON, P., THIEBLOT, P., GRIZARD, J. and OBLED, C. Whole-body protein turnover and hepatic protein synthesis are increased by vaccination in man. Clin Sci Colch 89, 389-396, 1995.
69. BIRO, J., BOSZE, S., HUDECZ, F., NAGY, Z., RAJNAVOLGYI, E., SCHMIDT, B., RAKASZ, E. and FALUS, A. The effect of WSEWS pentapeptide and WSEWS-specific monoclonal antibodies on constitutive and IL-6-induced acute phase protein production by a human hepatoma cell ine, HepG2. Immunol Lett 46, 183-187, 1995.
70. VASSE, M., COLLET, J.P., SORIA, J., MIRSHAHI, S.S., VANNIER, J.-P. and SORIA, C. Fibrinogen, a vascular risk factor: A simple marker or a real cause of vascular lesion? Thromb Res 75, 349-352, 1994.
71. KOPF, M., BAUMANN, H., FREER, G., FREUDENBERG, M., LAMERS, M., KISHIMOTO, T., ZINKERNAGEL, R., BLUETHMANN, H. and KOHLER, G. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 368, 339-342, 1994.
72. HANGLOW, A.C., ROSENBERGER, M., LOVEY, A.J., NEMZEK, R., WELTON, A.F. and COFFEY, J.W. Anti-inflammatory and immuno-modulatory effects of novel retinoid-like 2,4,6,8-nonatetraenoic acids (NTA) in adjuvant-induced arthritis. Agents Actions 27, 347-350, 1989.
73. RIIPI, L. and CARLSON, E. Tumor necrosis factor (TNF) is induced in mice by candida albicans: Role of TNF in fibrinogen increase. Infect Immun 58, 2750-2754, 1990.
74. VAN GOOL, J., VAN VUGT, H., HELLE, M. and AARDEN, L.A. Clin. Immunol Immunopathol 57, 200-210, 1990.
75. MILLER, L.L. and JOHN, D.W. Factors affecting net fibrinogen biosynthesis by the isolated perfused rat liver. Thromb Diath Haemorrh 39, 127-144, 1970.
76. MCKENZIE, J.M., CELANDER, D.R. and GUEST, M.M. Fibrinogen titer as an indicator of physiological stability. Am J Physiol 204, 42-44, 1963.
77. HENRIQUES, S.B., HENRIQUES, O.B. and LEVY A. Slow hyperfibrinogenaemic action of adrenaline and related substances. Br J Pharmacol 11, 99-103, 1956.
78. MORROW, L.E., MCCLELLAN, J.L., CONN. C.A. and KLUGER, M.J. Glucocorticoids alter fevel and IL-6 responses to psychological stress and to lipopolysaccharide. Am J Physiol 264, R1010-R1016, 1993.
79. SUZUKI, K., MIYASHITA, A., INOUE, Y., IKI, S., ENOMOTO, H., TAKAHASHI, Y and TAKEMURA, T. Interleukin-6-producing pheochromocytoma. Acta Haematol 85, 217-219, 1991.
80. GAVOTTO, A.C., PALMA, J.A. and VILLAGRA, S.B. Effects of indomethacin on plasma fibrinogen levels in rats with tissue injury. Arch Int Pharmacodyn Ther 274, 320-327, 1985.
81. MCKENZIE, J.M. and FOWLER, P.R. Supporting role of the adrenal cortex in the induction of hyperfibrinogenemia. Am J Physiol 214, 786-790, 1968.
82. COHEN, S. Role of the hypophysis in the plasma fibrinogen response to trauma. S Afr Med Sci 18, 85-89, 1953.
83. 1, bradykinin and histamine and the increase of plasma fibrinogen in rats. Prostaglandins 30, 879-886, 1985.
84. GAVOTTO, A.C., PALMA, J.A. and VILLAGRA, S.B. Role of histamine on plasma fibrinogen levels in rats with surgical injury (laparotomy). Arch Int Physiol Biochem 93, 175-179, 1985.
85. VELLENGA, E., VAN DER VINNE, B., DE WOLF, J.T.M. and HALIE, M.R. Simultaneous expression and regulation of G-CSF and IL-6 mRNA in adherent human monocytes and fibroblasts. Br J Haematol 78, 14-18, 1991.
86. WEETMAN, A.P., BRIGHT-THOMAS, R. and FREEMAN, M. Regulation of interleukin-6 release by human thyrocytes. J Endocrinol 127, 357-361, 1990.
87. DERIGS, H.G., BURGESS, G.S., KLINGBERG, D., NAHREINI, T.S., MOCHIZUKI, D.Y., WILLIAMS, D.E. and BOSWELL, H.S. Role for cyclic AMP in the postreceptor control of cytokine-stimulated stromal cell growth factor production. Leukemia 4, 471-479, 1990.
88. LÖWIK, C.W.G.M., VAN DER PLUIJM, G., BLOYS, H., HOEKMAN, K., BIJVOET, O.L.M., AARDEN, L.A. and PAPAPOULOS, S.E. Parathyroid hormone (PTH) and PTH-like protein (PLP) stimulate interleukin-6 production by osteogenic cells: A possible role of interleukin-6 in osteoclastogenesis. Biochem Biophys Res Commun 762, 1546-1552, 1989.
89. TANABE, O., AKIRA, S., KAMIYA, T., WONG, G.G., HIRANO, T. and KISHIMOTO, T. Genomic structure of the murine IL-6 gene. J Immunol 141, 3875-3881, 1988.
90. KANNEL, W.B., D'AGOSTINO, R.B. and BELANGER. A.J. Fibrinogen, cigarette smoking and risk of cardiovascular disease: Insights from the Framingham study. Am Heart J 113, 1006-1010, 1987.
91. ELIASSON, M., ASPLUND, K., EVRIN, P-E. and LUNDBLAD, D. Relationship of cigarette smoking and snuff dipping to plasma fibrinogen, fibrinolytic variables and serum insulin: The Northern Sweden Monica study. Atherosclerosis 113, 41-53, 1995.
92. SCARABIN, P.-Y., BARA, L., RICARD, S., POIRIER, O., CAMBOU, J.P., ARVEILER, D., LUC, G., EVANS, A.E., SAMAMA, M.M. and CAMBIEN, F. Genetic variation at the β-fibrinogen locus in relation to plasma fibrinogen concentrations and risk of myocardial infarction. The ECTIM study. Arterioscler Thromb 13, 886-891, 1993.
93. YARNELL, J.W.G., BAKER, I.A., SWEETNAM, P.M., BAINTON, D., O'BRIEN, J.R., WHITEHEAD, P.J. and ELWOOD, P.C. Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. Circulation 83, 836-844, 1991.
94. MEADE, T.W., IMESON, J. and STIRLING, Y. Effects of changes in smoking and other characteristics on clotting factors and the risk of ischaemic heart disease. Lancet ii, 986-988, 1987.
95. FEHER, M.D., RAMPLING, M.W., BROWN, J., ROBINSON, R., RICHMOND, W., CHOLERTON, S., BAIN, B.J. and SEVER, P.S. Acute changes in atherogenic and thrombogenic factors with cessation of smoking. J R Soc Med 83, 146-148, 1990.
96. ERNST, E. and MATRAI, A. Abstention from chronic cigarette smoking normalizes blood rheology. Atherosclerosis 64, 75-77, 1987.
97. TAGA, T., NARAZAKI, M., YASUKAWA, K., SAITO, T., MIKI, D., HAMAGUCHI, M., DAVIS, S., SHOYAB, M., YANCOPOULOS, G.D. and KISHIMOTO, T. Functional inhibition of hematopoietic and neurotrophic cytokines by blocking the interleukin 6 signal transducer gp130. Proc Natl Acad Sci USA 89, 10998-11001, 1992.
98. PETERS, M., ROEB, E., PENNICA, D., MEYER ZUM BUSCHENFELDE, K.H. and ROSE-JOHN, S. A new hepatocyte stimulating factor: Cardiotrophin-1 (CT-1). FEBS Lett 372, 177-180, 1995.
99. SCHOOLTINK, H., STOYAN, T., ROEB, E., HEINRICH, P.C. and ROSE-JOHN, S. Ciliary neurotrophic factor induces acute phase protein expression in hepatocytes. FEBS Lett 314, 280-284, 1992.
100. DOOLITTLE, R.F. Fibrinogen and fibrin. Annu Rev Biochem 53, 195-229, 1984.
101. ZHANG, J.-Z., KUDRYK, B. and REDMAN, C. Symmetrical disulfide bonds are not necessary for assembly and secretion of human fibrinogen. J Biol Chem 268, 11278-11282, 1993.
102. ZHANG, J.-Z. and REDMAN, C. Role of interchain disulfide bonds on the assembly and secretion of human fibrinogen. J Biol Chem 269, 652-658, 1994.
103. HUANG, S., CAO, Z. and DAVIE, E.W. The role of amino-terminal disulfide bonds in the structure and assembly of human fibrinogen. Biochem Biophys Res Commun 190, 488-495, 1993.
104. ZHANG, J.-Z. and REDMAN, C. Fibrinogen assembly and secretion. Role of intrachain disulfide loops. J Biol Chem 271, 30083-30088, 1996.
105. ROY, S.N., PROCYK, P., KUDRYK, B.J. and REDMAN, C.M. Assembly and secretion of recombinant human fibrinogen. J Biol Chem 266, 4758-4763, 1991.
106. ROY, S.N., MUKHOPADHYAY, G. and REDMAN, C.M. Regulation of fibrinogen assembly. Transfection of Hep G2 cells with Bβ cDNA specifically enhances synthesis of the three component chains of fibrinogen. J Biol Chem 265, 6389-6393, 1990.
107. ROY, S.N., OVERTON, O. and REDMAN, C.M. Overexpression of any fibrinogen chain by Hep G2 cells specifically elevates the expression of the other two chains. J Biol Chem 269, 691-695, 1994.
108. YU, S., KONG, V., KUDRYK, B. and REDMAN, C. Endogenous forms of fibrinogen in Hep G2 cells. Thromb Res 46, 281-293, 1987.
109. HIROSE, S., ODA, K. and IKEHARA, Y. Biosynthesis, assembly and secretion of fibrinogen in cultured rat hepatocytes. Biochem J 251, 373-377, 1988.
110. ROY, S., YU, S., BANERJEE, D., OVERTON, O., MUKHOPADHYAY, G., ODDOUX, C. GRIENINGER, G. and REDMAN, C. Assembly and secretion of fibrinogen. Degradation of individual chains. J Biol Chem 267, 23151-23158, 1992.
111. HARTWIG, R. and DANISHEFSKY, K.J. Studies on the assembly and secretion of fibrinogen. J Biol Chem 266, 6578-6585, 1991.
112. ROY, S.N., KUDRYK, B. and REDMAN, C.M. Secretion of biologically active recombinant fibrinogen by yeast. J Biol Chem 270, 23761-23767, 1995.
113. ZHANG, Z., FUENTES, N.L. and FULLER, G.M. Characterization of the IL-6 responsive elements in the gamma fibrinogen gene promoter. J Biol Chem 270, 24287-24291, 1995.
114. GRIENINGER, G., PLANT, P.W., LIANG, T.J., KALB, R.G., AMRANI, D., MOSESSON, M.W., HERTZBERG, K.M. and PINDYCK, J. Hormonal regulation of fibrinogen synthesis in cultured hepatocytes. Ann NY Acad Sci 408, 469-488.
115. JIANG, S.L., SAMOLS, D., RZEWNICKI, D., MACINTYRE, S.S., GREBER, I., SIIPE, J. and KUSHNER, I. Kinetic modeling and mathematical analysis indicate that acute phase gene expression in Hep 3B cells is regulated by both transcriptional and posttranscriptional mechanisms. J Clin Invest 95, 1253-1261, 1995.
116. EASTMAN, E.M. and GILULA, N.B. Cloning and characterization of a cDNA for the Bβ chain of rat fibrinogen: Evolutionary conservation of translated and 3′-untranslated sequences. Gene 79, 151-158, 1989.
117. SIXMA, J.J. and DE GROOT, P.G. The ideal anti-thrombotic drug. Thromb Res 67, 305-311, 1992.
118. REININGER, A.J., REININGER, C.B., SPANNAGL, M., MELLINGHOFF, A., PORR, A., HEINZMANN, U. and WURZINGER, L.J. Effect of fibrinogen substitution in afibrinogenemia on hemorheology and platelet function. Thromb Haemost 3, 853-858, 1995.
119. PRESTON, F.E., BURAKOWSKI, B.K., PROTER, N.R. and MALIA, R.G. The fibrinolytic response to stanozolol in normal subjects. Thromb Res 22, 543-551, 1981.
120. JARRETT, P.E.M., MORLAND, M. and BROWSE, N.L. Treatment of Raynaud's phenomenon by fibrinolytic enhancement. Br Med J 2, 523-525, 1978.
121. FEHER, K.G., RAKASZ, E., BIRO, J. and FALUS, A. Dehydroepiandrosterone modulates the spontaneous and IL-6 stimulated fibrinogen production of human hepatoma cells. Acta Microbiol Immunol Hung 42, 229-233, 1995.
122. KESSLER, C.M. and BELL, W.R. Stimulation of fibrinogen synthesis: A possible functional role of fibrinogen degradation products. Blood 55, 40-47, 1980.
123. VAN PELT-VERKUIL, E., VAN DE REE, P. and EMEIS, J.J. Defibrinogenation by arvin reduces air-drying-induced arteriosclerosis in rat carotid artery. Thromb Haemost 61, 246-249, 1989.
124. POSTLETHWAITE, J.C., GOYLE, K.B., DORMANDY, J.A. and HYND, J.W. Improvement in experimental vascular graft patency by controlled defibrinogenation. Br J Surg 64, 28-30, 1977.
125. SCHUMACHER, W.A., HERAN, C.L. and STEINBACHER, T.E. Sensitivity of experimental venous and arterial thrombosis and bleeding to ancrod-induced defibrinogenation. Thromb Res 81, 187-194, 1996.
126. SOUTAR, R.L. and GINSBERG, J.S. Anticoagulant therapy with ancrod. Crit Rev Oncol Hematol 15, 23-33, 1993.
127. BELL, W.R., PITNEY, W.R. and GOODWIN, J.F. Therapeutic defibrination in the treatment of thrombotic disease. Lancet i, 490-493, 1968.
128. CATTANEO, M., BETTEGA. D., LOMBARDI. R., LECCHI, A. and MANNUCCI, P.M. Sustained correction of the bleeding time in an afibrinogenaemic patient after infusion of fresh frozen plasma. Br J Haematol 82, 388-390, 1992.
129. EHRINGER, H., DUDCZAK, R. and LECHNER, K. A new approach in the treatment of peripheral arterial occlusions: Defibrination with arvin. Angiology 27, 279-289, 1974.
130. LOWE, G.D.O., CAMPBELL, A.F., MEEK, D.R., FORBES, C.D., PRENTICE, C.R.M. and CUMMINGS, S.W. Subcutaneous ancrod in prevention of deep-vein thrombosis after operation for fractured neck of femur. Lancet ii, 698-700, 1978.
131. LATALLO, Z.S. Retrospective study on complications and adverse effects of treatment with thrombin-like enzymes - A multicentre trial. Thromb Haemost 50, 604-609, 1983.
132. KORNALIK, F. Inhibition of experimental arterial and venous thrombosis by ecarin, a defibrinating enzyme. Folia Haematol 104, 833-838, 1977.
133. A. CHAN, K.E. The comparison of the antithrombotic action of the thrombin-like fraction of malayan pit viper venom and heparin. Cardiovasc Res 3, 171-178, 1969.
134. A. AL BALLA, S., AL MOMEN, A.K., AL ARFAJ, H., AL SUGAIR, S. and GADER, A.M.A. Interaction between nabumetone - a new nonsteroidal anti-inflammatory drug - and the haemostatic system ex vivo. Haemostasis 20, 270-275, 1990.
135. GOUGH, S.C.L., PULLAR, T., RICE, P.J.S., ZEBOUNI, L. and GRANT, P.J. Fibrinolytic activity in rheumatoid arthritis and the effect of prednisolone therapy. Fibrinolysis 1, 97-101, 1991.
136. RAMSAY, N.K.C., COCCIA, P.F., KRIVIT, W., NESBIT, M.E. and EDSON, J.R. The effect of L-asparaginase on plasma coagulation factors in acute lymphoblastic leukemia. Cancer 40, 1398-1401, 1977.
137. SAITO, M., ASAKURA, H., JOKAJI, H., UOTANI, C., KUMABASHIRI, I., ITO, K. and MATSUDA, T. Changes in hemostatic and fibrinolytic proteins in patients receiving L-asparaginase therapy. Am J Hematol 32, 20-23, 1989.
138. MUSS, H.B., SPELL, N., SCUDIERY, D., CAPIZZI, R.L., COOPER, M.R., CRUZ, J., JACKSON, D. V., RICHARDS, F., II, SPURR, C.L., WHITE, D.R., ZEKAN, P.J. and FRANKLIN, A., A phase II trial of peg-L-asparaginase in the treatment of nonhodgkins lymphoma. Invest New Drugs 8, 125-130, 1990.
139. SALMASI, A.-M., SALMASI, S., MACDONALD, G. and NICOLAIDES, A.N. Improvement of silent myocardial ischaemia and reduction of plasma fibrinogen during nisoldipine therapy in occult coronary arterial disease. Int J Cardiol 31, 71-80, 1991.
140. MEHROTRA, T.N., MITAL, H.S., SINGH, V.S. KUMAR, A., SINHA, A.K. and RAKA, M.S. Platelet adhesiveness, plasma fibrinogen and fibrinolytic activity in angina pectoris before and after propranolol therapy. J Assoc Phys India 31, 641-643, 1983.
141. HERMANN, J.M. and MAYER, E.O. A long-term study of the effects of celiprolol on blood pressure and lipid-associated risk factors. Am Heart J 116, 1416-1421, 1988.
142. BERGLUND, U., WALLENTIN, L. and VON SCHENCK, H. Platelet function and plasma fibrinogen and their relations to gender, smoking habits, obesity and beta-blocker treatment in young survivors of myocardial infarction. Thromb Haemost 60, 21-24, 1988.
143. FOGARI, R., ZOPPI, A., MALAMANI, G. D., MARASI, G., VANASIA, A. and VILLA, G. Effects of different antihypertensive drugs on plasma fibrinogen in antihypertensive patients. Br J Clin Pharmacol 39, 471-476, 1995.
144. FEARNLEY, G.R., CHAKRABARTI, R. and EVANS, J.F. Fibrinolytic treatment of rheumatoid arthritis with phenformin plus ethyl stronol. Lancet ii, 757-761, 1966.
145. FEARNLEY, G.R., CHAKRABARTI, R., HOCKING, E.D. and EVANS, J.F. Phenformin in rheumatoid arthritis: A fibrinolytic approach. Lancet i, 9-13, 1965.
146. 125I-fibrinogen survival. J Clin Pathol 23, 797-800, 1970.
147. NILSSON, I.M., HEDNER, U. and ISACSON, S. Phenformin and ethyloestrenol in recurrent venous thrombosis. Acta Med Scand 198, 107-113, 1975.
148. LOTZ-WINTER, H. On the pharmacology of bromelain: An update with special regard to animal studies on dose-dependent effects. Planta Med 56, 249-253, 1990.
149. DIDISHEIM, P. and LEWIS, J.H. Fibrinolytic and coagulant activities of certain snake venoms and proteases. PSEBM 93, 10-13, 1956.
150. SMITH, R.D., BRENNAN, R. and MARTIN, G.J. Systemic biochemical changes following the oral administration of a proteolytic enzyme, bromelain. Arch Int Pharmacodyn 86, 230-236, 1962.
151. FAREED, J., WALENGA, J.M., HOPPENSTEADT, D.A., KUMAR, A., ULUTIN, O.N. and CORNELLI, U. Pharmacologic profiling of defibrotide in experimental models. Semin Thromb Haemost 14, 27-37, 1988.
152. CAPPELLI, R., PECCHI, S., PIERAGALLI, D., ACCIAVATTI, A., GALIGANI, C., MESSA, G.L., VITTORIA, A., GUERRINI, M., FORCONI, S. and DIPERRI, T. Effect on rheological and some peripheral haemodynamic parameters of defibrotide in POAD patients. Clin Hemorheol 7, 247-252, 1987.
153. NIORT, G., BURGARELLI, A., CASSADER, M. and PAGANO, G. Effect of short-term with bezafibrate on plasma fibrinogen, fibrinopeptide A, platelet activation and blood filterability in atherosclerotic hyperfibrinogenemic patients. Atherosclerosis 71, 113-119, 1988.
154. BARBIR, M., HUNT, B., KUSHWAHA, S., KEHELY, A., PRESCOT, R., THOMPSON, G.R., MITCHELL, A. and YACOUB, M. Maxepa vs. bezafibrate in hyperlipidemic cardiac transplant recipients. Am J Cardiol 70, 1596-1601, 1992.
155. DORMANDY, J.A. GUTTERIDGE, J.M.C., HOARE, E. and DORMANDY, T.L. Effect of clofibrate on blood viscosity in intermittent claudication. Br Med J 4, 259-262, 1974.
156. FLETCHER, A., ALKJAERSIG, N. SCHONFELD, G. and WITZTUM, J. Fibrinogen catabolism in patients with type II and Type IV hyperlipidemia. Arteriosclerosis 1, 202-209, 1981.
157. OHTANI, Y. Long-term treatment with clofibrate (Atromid). Observation of plasma-fibrinogen and serum-lipids. Clin Trials J 3, 106-116, 1977.
158. SPOTTL, F. and FROSCHAUER, J. Influence of etofibrate on plasma fibrinogen and plasminogen concentrations in patients with different forms of primary hyperlipoproteinemia. Atherosclerosis 25, 293-301, 1976.
159. BRANCHI, A., ROVELLINI, A., SOMMARIVA, D., GUGLIANDOLO, A.G. and FASOLI, A. Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia. Thromb Haemost 70, 241-243, 1993.
160. BROIJERSEN, A., HAMSTEN, A., SILVEIRA, A., FATAH, K., GOODALL, A.H. ERIKSSON, M., ANGELIN, B. and HJEMDAHL, P. Gemfibrozil reduces thrombin generation in patients with combined hyperlipidaemia, without influencing plasma fibrinogen, fibrin gel structure or coagulation factor VII. Thromb Haemost 76, 171-176, 1996.
161. CALVERT, G.D., BLIGHT, L., FRANKLIN, J., OLIVER, J., WISE, P. and GALLUS, A.S. The effects of clofibrate on plasma glucose, lipoproteins, fibrinogen, and other biochemical and haematological variables in patients with mature onset diabetes mellitus. Eur J Pharmacol 17, 355-362, 1980.
162. SIMON B., SIMON C.G., KATHER, H. and HEIDELBERG, G. Inhibition of human fat cell adenyl cyclase by clofibrate. Eur J Clin Invest 4, 326, 1976.
163. CARLSON, L.A., WALLDIUS, G., and BUTCHER, R.W. Effect of chlorophenoxyisobutyric acid (CPIB) on fat-mobilizing lipolysis and cyclic AMP levels in rat epididymal fat. Atherosclerosis 3, 349-357, 1972.
164. D'COSTA, M., SMIGURA, F. and ANGEL, A. Antilipolytic effect of clofibrate; A possible role in its hypolipidemic action. Circulation 4, 15, 1973.
165. PICKART, L. Suppression of acute-phase synthesis of fibrinogen by a hypolipidemic drug (clofibrate). Int J Tissue React 2, 65-72, 1981.
166. BARRETT, A.M. The role of plasma free fatty acids in the elevation of plasma cholesterol and phospholipids produced by adrenaline. J Endocrinol 36, 301-316, 1966.
167. PICKART, L. Free fatty acidemia as an inducer of systemic hyperfibrinogenemia and fibrinolytic inhibition. Inflammation 5, 61-70, 1981.
168. HOAK, J.C., CONNOR, W.E. and WARNER, E.D. Thrombogenic effects of albumin-bound fatty acids. Arch Pathol 81, 136-139, 1966.
169. MAYER, J., ELLER, T., BRAUER, P., SOLLEDER, E.M., SCHAFER, R.M., KELLER, E. and KOCHSIEK, K. Effects of long-term treatment with lovastatin on the clotting system and blood platelets. Ann Hematol 64, 196-201, 1992.
170. BEIGEL, Y., FUCHS, J., SNIR, M., LURIE, Y., GREEN, P. and DJALDETTI, M. Lovastatin therapy in heterozygous familial hypercholesterolaemic patients: Effect on blood rheology and fibrinogen levels. J Intern Med 230, 23-27, 1991.
171. BEIGEL, Y., FUCHS, J., SNIR, M., GREEN, P., LURIE, Y. and DJALDETTI, M. Lovastatin therapy in hypercholesterolemia: Effect on fibrinogen, hemorrheologic parameters, platelet activity, and red blood cell morphology. J Clin Pharmacol 31, 512-517, 1991.
172. JAY, R.H., RAMPLING, M.W. and BETTERIDGE, D.J. Abnormalities of blood rheology in familial hypercholesterolaemia: Effects of treatment. Atherosclerosis 85, 24249-256, 1990.
173. OREFICE, G., TROISI, E., SELVAGGIO, M., VECCHIONE, V., RUBINO, S., PROVITERA, V. and CARRIERI, P.B. Effect of long-term mesoglycan treatment on fibrinogen plasma levels in patients with ischemic cerebrovascular disease. Curr Ther Res 52, 666-670, 1992.
174. PICKART, L. and THALER, M.M. Fatty acids, fibrinogen and blood flow: A general mechanism for hyperfibrinogenemia and its pathologic consequences. Med Hypoth 6, 545-557, 1980.
175. HANSON, P.G., JOHNSON, R.E. and ENGEL, G. Plasma free fatty acid changes in man during acute cold exposure and nicotinic acid ingestion. Aerospace Med 11, 1054-1058, 1965.
176. DAVIS, E. and ROZOV, H. The effects of xanthinol nicotinate on the small blood vessels. Bibl Anat 11, 334-339, 1973.
177. MATSUNAGA, A., HANDA, K., MORI, T., MORIYAMA, K., HIDAKA, K., YUKI, M., SASAKI, J. and ARAKAWA, K. Effects of niceritrol on levels of serum lipids, lipoprotein(a), and fibrinogen in patients with primary hypercholesterolemia. Atherosclerosis 94, 241-248, 1992.
178. BENAIM, M.E. and DEWAR, H.A. The effect of tetranicotinoylfructose on fibrinolytic activity, platelet stickiness and some other parameters. J Int Med Res 3, 423-427, 1975.
179. FRANCESCHINI. G. and PAOLETTI, R. Pharmacological control of hypertriglyceridemia. Cardiovasc Drugs Ther 7, 297-302, 1993.
180. RACCUGLIA, G. Influence of dietary trans, trans-linoleate on hematologic and hemostatic properties of rat blood. Lipids 5, 85-89, 1969.
181. SAYNOR R. and GILLOTT, T. Changes in blood lipids and fibrinogen with a note on safety in a long term study on the effects of n-3 fatty acids in subjects receiving fish oil supplements and followed for seven years. Lipids 27, 533-538, 1992.
182. GEILL, T. and DYBKAER, R. The effect of linolenic acid orally on platelet adhesiveness and fibrinogen concentration. Scand J Clin Lab Invest 23, 255-258, 1969.
183. HAGLUND, O., HAMFELT, A., HAMBRAEUS, L. and SALDEEN, T. Effects of fish oil supplemented with pyridoxine and folic acid on homocysteine, atherogenic index, fibrinogen and plasminogen activator inhibitor-1 in man. Nutr Res 13, 1351-1365, 1993.
184. RADACK, K., DECK, C. and HUSTER, G. Dietary supplementation with low-dose fish oils lowers fibrinogen levels: A randomized, double-blind controlled study. Ann Intern Med 111, 757-758, 1989.
185. MUELLER, R. On the therapy of disturbances of blood fluidity. Angiology 36, 226-234, 1985.
186. PERRI, T., CARANDENTE, O., VITTORIA, A., GUERRINI, M. and MESSA, G. Studies of the clinical pharmacology and the therapeutic efficacy of pentoxifylline in peripheral occlusive arterial disease. Angiology 35, 427-435, 1984
187. BACHET, P., LANCRENON, C. and CHASSOUX, G. Fibrinogen and pentoxifylline. Thromb Res 55, 161-163, 1989.
188. STRANO, A., DAVI, G., AVELLONE, G., NOVO, S. and PINTO, A. Double-blind, crossover study of the clinical efficacy and the hemorheological effects of pentoxifylline in patients with occlusive arterial disease of the lower limbs. Angiology 35, 459-466, 1984.
189. ANGELKORT, B., PIRNAY, D., KIESEWETTER, H. and MAURIN, N. Hemodilution and pentoxifylline effects on muscle bllod flow and blood fluidity in chronic arterial occlusive disease. Vase Med 1, 150-158; 1983.
190. DROUET, L. Fibrinogen: A treatable risk factor? Cerebrovasc Dis 6, 2-6, 1996.
191. AUKLAND, A., HURLOW, R.A., GEORGE, A.J., STUART, J. Platelet inhibition with ticlopidine in atherosclerosis intermittent claudication. J Clin Pathol 35, 740-743, 1982.
192. CONARD, J., LECRUBIER, C., SCARABIN, P.Y., HORELLOU, M.H., SAMAMA, M. and BOUSSER, M.G. Effects of long term administration of ticlopidine on platelet function and hemostatic variables. Thromb Res 20, 143-148, 1980.
193. MAZOYER, E., RIPOLL, L., BOISEAU, M.R. and DROUET, L. How does ticlopidine treatment lower plasma fibrinogen? Thromb Res 75, 361-370, 1994.
194. ALVING, B.M., BELL, W.R. and EVATT, B.L. Fibrinogen synthesis in rabbits: Effects of altered levels of circulating fibrinogen. Am J Physiol 241, H478-H484, 1977.
195. PILGERAM L.O. and PICKART L.R. Control of fibrinogen biosynthesis: The role of free fatty acid. J Atheroscler Res 8, 155-166, 1968.
196. PICKART, L.R. and PILGERAM, L.O. The role of thrombin in fibrinogen biosynthesis. Thromb Diath Haemorrh 17, 358-364, 1967.
197. ALVING, B.M., EVATT, B.L. and BELL, W.R. Stimulation of fibrinogen synthesis by thrombin in rabbits with ancrod-induced afibrinogenemia. Am J Physiol 233, H562-H567, 1977.
198. KROPATKIN, M.L. and IZAK, G. Studies on the hypercoagulable state. Thromb Diath Haemorrh 19, 547-555, 1968.
199. SHARP, A.A., WARREN, B.A., PAXTON, A.M. and ALLINGTON, M.J. Anticoagulant therapy with a purified fraction of malayan pit viper venom. Lancet i, 493-499, 1968.
200. FRANCIS, C.W. and KORNBERG, A. Fibrinogen- and fibrin-degradation products during fibrinolytic therapy. Ann NY Acad Sci 667, 310-323, 1992.
201. TAKAHASHI, H., WADA, K., HANANO, M., NIWANO, H., TAKIZAWA, S., YAZAWA, Y. and SHIBATA, A. Fibrinolysis and fibrinogenolysis in patients with thrombotic disease. Blood Coagul Fibrinol 3, 193-196, 1992.
202. PELTONEN, S., KAUHANEN, P., LEPANTALO, M. and LASSILA, R. The severity of atherosclerosis is associated with fibrinogen and degradation of cross-linked fibrin. Fibrinolysis 6, 31-32, 1992.
203. PRINCEN, H.M.G., MOSHAGE, H.J., EMEIS, J.J., DE HAARD, H.J.W, NIEUWENHUIZEN, W. and YAP, S.H. Fibrinogen fragments X, Y, D and E increase levels of plasma fibrinogen and liver mRNAs coding for fibrinogen polypeptides in rats. Thromb Haemost 53, 212-215, 1985.
204. LEWIS, J.H. Effects of epsilon amino caproic acid (EACA) on survival of fibrinogen 1131 and on fibrinolytic and coagulation factors in dogs. Proc Soc Exp Med Biol 114, 777-778, 1963.
205. KESSLER, C.M. and BELL, W.R. The effect of homologous thrombin and fibrinogen degradation products on fibrinogen synthesis in rabbits. J Lab Clin Med 93, 768-782, 1979.
206. COLLEN, D., TYTGAT, G.N. CLAEYS, H., VERSTRAETE, M. and WALLEN, P. Metabolism of plasminogen in healthy subjects: Effect of tranexamic acid. J Clin Invest 51, 1310-1318, 1972.
207. COLLEN, D., TYTGAT, G.N. CLAEYS, H. and PIESSENS, R. Metabolism and distribution of fibrinogen: Fibrinogen turnover in physiocological conditions in humans. Br J Haematol 22, 681-700, 1972.
208. REEVE, E.B. and FRANKS, J.J. Fibrinogen synthesis, distribution and degradation. Semin Thromb Haemost 1, 129-183, 1974.
209. COMP, P.C. Life-span of plasma coagulation factors. In: Hematology. W. J. Williams, E. Beutler, A. J. Erslev and M. A. Lichtman (eds,), pp. 289-1294, McGraw-Hill, Inc., New York (1988).
210. MALOFIEJEW, M. The biological and pharmacological properties of some fibrinogen degradation products. Scan J Haematol 13, 303-308, 1970.
211. MOSHAGE, H.J., PRINCEN, H.M.G., PELT, J.V., ROELOFS, H.M.J., NIEUWENHUIZEN, W. and YAP, S.H. Differential effects of endotoxin and fibrinogen degradation products (FDPS) on liver synthesis of fibrinogen and albumin: Evidence for the involvement of a novel monokine in the stimulation of fibrinogen synthesis induced by FDPS. Int J Biochem 22, 1393-1400, 1990.
212. RITCHIE, D.G., LEVY, B.A., ADAMS, M.A. and FULLER, G.M. Regulation of fibrinogen synthesis by plasmin-derived fragments of fibrinogen and fibrin: An indirect feedback pathway. Proc Natl Acad Sci USA 79, 1530-1534, 1982.
213. MANDL, J., CSALA, M., LERANT, I., BANHEGYI, G., BIRO, J., MACHOVICH, R. and FALUS, A. Enhancement of interleukin-6 production by fibrinogen degradation product D in human peripheral monocytes and perfused murine liver. Scand J Immunol 42, 175-178, 1995.
214. BOCCI, V., CONTI, T., MUSCETTOLA, M., PACINI, A. and PESSINA, G.P. Factors regulating plasma protein synthesis IV. Influence of fragments D and E on plasma fibrinogen concentration. Thromb Diath Haemorrh 31, 395-402, 1974.
215. FRANKS, J.J., KIRSCH, R.E., FRITH, L.O'C., PURVES, L.R., FRANKS, W.T. and FRANKS, J.A. Effect of fibrinogenolytic products D and E on fibrinogen and albumin synthesis in the rat. J Clin Invest 67, 575-580, 1981.
216. BELL, W.R., KESSLER, C.M. and TOWNSEND, R.R. Stimulation of fibrinogen biosynthesis by fibrinogen fragments D and E. Br J Haematol 53, 599-610, 1983.
217. BOCCI, V. and PACINI, A. Factors regulating plasma protein synthesis. Thromb Diath Haemorrh 29, 63-75, 1973.
218. BARNHART, M.I., CRESS, D.C., NOONAN, S.M. and WALSH, R.T. Influence of fibrino lytic products on hepatic release and synthesis of fibrinogen. Thromb Diath Haemorrh 39, 143-159, 1970.
219. SMITH, E.B., KEEN, A., GRANT, A. and STIRK, C. Fate of fibrinogen in human arterial intima. Arteriosclerosis 10, 263-275, 1990.
220. ROBSON, S.C., SHEPARD, E.G. and KIRSCH, R.E. Fibrin degradation product D-dimer induces the synthesis and release of biologically active IL-1β, IL-6 and plasminogen activator inhibitors from monocytes in vitro. Br J Haematol 86, 322-326, 1994.
221. LADUCA, F.M., TINSLEY, L. A., DANG, C.V. and BELL W.R. Stimulation of fibrinogen synthesis in cultured rat hepatocytes by fibrinogen degradation product fragment D. Proc NatL Acad Sci USA 86, 8788-8792, 1989.
222. LOIRE, J.D., ET AL. CD11c/CD18 on neutrophils recognize a domain at the N terminus of the Aa chain of fibrinogen. Proc Natl Acad Sci USA 88, 1044, 1991.
223. TREZZINI, C., JUNGI, T.W., KUHNERT, P. and PETERHANS, E. Fibrinogen association with human monocytes: Evidence for constitutive expression of fibrinogen receptors and for involvement of Mac-1 (CD18, CR3) in the binding. Biochem Biophys Res Commun 156, 477-484, 1988.
224. ALTIERI, D.C., BADER, R., MANNUCCI, P.M. and EDGINGTON, T.S. Oligospecificity of the cellular adhesion receptor MAC-1 encompasses an inducible recognition specificity for fibrinogen. J Cell Biol 107, 1893-1900, 1988.
225. TREZZINI, C., JUNGI, T.W., MALY, F.E., VITTOZ, M. and PETERHANS, E. Low-affinity interaction of fibrinogen carboxy-gamma terminus with human monocytes induces an oxidative burst and modulates effector functions. Biochem Biophys Res Commun 165, 7-13, 1989.
226. PICKART, L. Fat metabolism, the fibrinogen/fibrinolytic system and blood flow: new potentials for the pharmacological treatment of coronary heart disease. Pharmacology 23, 271-280, 1981.
227. HONSTRA, G. Dietary prevention of coronary heart disease. Effect of dietary fats on arterial thrombosis. Postgrad Med J 56, 563-570, 1980.
228. PICKART, R. and THALER, M.M. Free fatty acids and albumin as mediators of thrombin-stimulated fibrinogen synthesis. Am J Physiol 230, 996-1002, 1976.
229. SIMPSON, H.C.R., MEADE, T.W., STIRLING, Y., MANN, J.I., CHAKRABARTI, R. and WOOLF, L. Hypertriglyceridaemia and hypercoagulability. Lancet i, 786-789, 1983.
230. DIXON, J.L., FURUKAWA, S. and GINSBERG, H.N. Oleate stimulates secretion of apolipoprotein B-containing lipoproteins from the HepG2 cells by inhibiting early intracellular degradation of apolipoprotein B. J Biol Chem 266, 5080-5086, 1991.
231. WHITE, A.L, GRAHAM, D.L., LEGROS, J., PEASE, R.J. and SCOTT, J. Oleate-mediated stimulation of apolipoprotein B secretion from rat hepatoma cells. J Biol Chem 267, 15657-15664, 1992.
232. MIZUGUCHI, J., HU, C.H., CAO, Z., LOEB, K.R., CHUNG, D.W. and DAVIE, E.W. Characterization of the 5′-flanking region of the gene for the gamma chain of human fibrinogen. J Biol Chem 270, 28350-28356 1995.
233. DALMON, J., LAURENT, M. and COURTOIS, G. The human beta fibrinogen promoter contains a hepatocyte nuclear factor 1-dependent interleukin-6-responsive element. Mol Cell Biol 13, 1183-1193, 1993.
234. COURTOIS, G., MORGAN, J.G., CAMPBELL, L.A., FOUREL, G. and CRABTREE, G.R. Interaction of a liver-specific nuclear factor with the fibrinogen and α1-antitrypsin promoters. Science 238, 688-692, 1987.
235. HU, C.G., HARRIS, J.E., DAVIE, E.W. and CHUNG, D.W. Characterization of the 5′-flanking region of the gene for the alpha chain of human fibrinogen. J Biol Chem 270, 28342-28349, 1995.
236. HUBER, P., LAURENT, M. and DALMON, J. Human beta-fibrinogen gene expression. Upstream sequences involved in its tissue specific expression and its dexamethasone and interleukin 6 stimulation. J Biol Chem 265, 5695-5701, 1990.
237. ANDERSON, G.M., SHAW, A.R. and SCHAFER, J.A. Functional characterization of promoter elements involved in regulation of human B beta-fibrinogen expression. Evidence for binding of novel activator and repressor proteins. J Biol Chem 268, 22650-22655, 1993.
238. ROSE-JOHN, S., SCHOOLTINK, H., LENZ, D., HIPP, E., DUFHUES, G., SCHMITZ, H. SCHIEL, X., HIRANO, T., KISHIMOTO, T. and HEINRICH, P.C. Studies on the structure and regulation of the human hepatic interleukin-6 receptor. Eur J Biochem 790, 79-83, 1990.
239. SCHOOLTINK, H., SCHMITZ-VAN DE LEUR, H., HEINRICH, P.C. and ROSE-JOHN, S. Up-regulation of the interleukin-6-signal transducing protein (gp130) by interleukin-6 and dexamethasone in HepG2 cells. FEBS Lett 297, 263-265, 1992.
240. ALAM, T., AN, M.R., MIFFLIN, R.C., HSIEH, C.C., GE, X., and PAPACONSTANTINOU, J. Trans-activation of the alpha 1-acid glycoprotein gene acute phase responsive element by multiple isoforms of C/EBP and glucocorticoid receptor. J Biol Chem 268, 15681-15688, 1993.
241. LIU, Z. and FULLER, G.M. Detection of a novel transcription factor for the A alpha fibrinogen gene in response to interleukin-6. J Biol Chem 270, 7580-7586, 1995.
242. ZHANG, J.-Z., KUDRYK, B. and REDMAN, C. Secretion of biologically active recombinant fibrinogen by yeast. J Biol Chem 270, 23761-23767, 1995.